(0.04%) 5 471.64 points
(0.09%) 39 146 points
(0.36%) 17 782 points
(0.01%) $80.84
(-3.66%) $2.66
(-0.80%) $2 312.10
(0.18%) $28.92
(3.49%) $1 020.80
(0.26%) $0.936
(0.68%) $10.68
(0.42%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals...
Stats | |
---|---|
今日成交量 | 5.54M |
平均成交量 | 3.03M |
市值 | 0.00 |
EPS | $-0.220 ( Q3 | 2021-11-09 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.989 (2.59%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-12-28 | Koppel Adam | Sell | 3 080 237 | Common Stock |
2021-12-28 | Koppel Adam | Sell | 3 333 | Restricted Stock Units |
2021-12-28 | Koppel Adam | Sell | 25 000 | Director Stock Option (Right to Buy) |
2021-12-28 | Koppel Adam | Sell | 25 000 | Director Stock Option (Right to Buy) |
2021-12-28 | Koppel Adam | Sell | 25 000 | Director Stock Option (Right to Buy) |
INSIDER POWER |
---|
0.00 |
Last 100 transactions |
Buy: 12 087 | Sell: 8 528 928 |
音量 相关性
Dicerna Pharmaceuticals 相关性 - 货币/商品
Dicerna Pharmaceuticals 财务报表
Annual | 2020 |
营收: | $164.31M |
毛利润: | $164.31M (100.00 %) |
EPS: | $-1.520 |
FY | 2020 |
营收: | $164.31M |
毛利润: | $164.31M (100.00 %) |
EPS: | $-1.520 |
FY | 2019 |
营收: | $23.90M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.760 |
FY | 2018 |
营收: | $6.18M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.600 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。